Keywords
Diabetic Kidney Disease
Mineralocorticoid Antagonist
Spironolactone
Eplerenone
diabetes mellitus
How to Cite
Abstract
Background: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) worldwide and has a direct impact on cardiovascular risk and mortality in patients with diabetes mellitus (DM). Finerenone, a selective mineralocorticoid receptor (MRA) antagonist, has been described in several recent studies as a drug that contributes to slowing the progression of CKD and reducing cardiovascular risk, with an adequate safety profile.
Purpose: To carry out a review of the literature on the impact of finerenone on the progression of renal damage and cardiovascular risk in patients with DKD.
Methodology: A systematic search were carried out in various sources: PubMed (Medline, United States Library of Congress), Science Direct, Scopus, Embase and Lilacs; the search was restricted to references in Spanish and English, with no limits on publication date. The following keywords in the English language were used: diabetic renal disease, chronic kidney disease, diabetes mellitus, spironolactone, eplerenone, finerenone, mineralocorticoid receptor antagonist and their corresponding Spanish versions.
Results: The references found in the search were reviewed among the different authors to subsequently proceed to prepare the document.
Conclusions: Finerenone is a drug that provides cardio and nephroprotection in patients with DKD albuminuric phenotype.
References
Castillo GA, Aroca G, Buelvas J, Buitrago AF, Carballo V, Cárdenas JM, et al. Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2. Rev Colomb Cardiol. 2020;27(supl. 3):3-22. https://doi.org/10.1016/j.rccar.2020.07.005
Rico-Fontalvo JE. Guía de práctica clínica para la enfermedad renal diabética. Rev Colomb Nefrol. 2021;8(2). https://doi.org/10.22265/acnef.8.2.561
American Diabetes Association. Microvascular complications and foot care: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(supl. 1):S151-67. https://doi.org/10.2337/dc21-S011
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021. Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):S1-87. https://doi.org/10.1016/j.kint.2020.11.003
Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular mechanisms of diabetic kidney disease. Int J Mol Sci. 2022;23(15):8668. https://doi.org/10.3390/ijms23158668
Rico-Fontalvo JE, Daza-Anedo R, Raad-Sarabia M, Pájaro-Galvis N, Bello-Espinosa A, Uparella-Gulfo I, et al. Proteoma urinario en la enfermedad renal diabética. Estado del arte. Rev Colomb Nefrol. 2021;8(3). http://dx.doi.org/10.22265/acnef.8.3.546
Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Develop Res. 2021;82(3):341-63. https://doi.org/10.1002/ddr.21760
Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. DCCT reseach trial. N Engl J Med. 1993. https://www.nejm.org/doi/full/10.1056/NEJM199309303291401
The Lancet. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62. https://doi.org/10.1056/NEJM199311113292004
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Engl J Med. 2001;345:851-60. https://doi.org/10.1056/NEJMoa011303
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med. 2001;345:861-69. https://doi.org/10.1056/NEJMoa011161
Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift fur Gefassmedizin. 2016. https://doi.org/10.1056/nejmoa1504720
Mahaffey KW, Neal B, Perkovic V, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
Rico-Fontalvo J, Daza-Arnedo R, Cardona-Blanco MX, Leal-Martínez V, Abuabara E, Pajaro-Galvis N, et al. SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J Clin Nephrol. 2020;4:44-55. https://doi.org/10.29328/journal.jcn.1001058
Rico-Fontalvo J, Vázquez-Jiménez LC, Rodríguez-Yánez T, Daza-Arnedo R, Raad-Sarabia M, Montejo-Hernández JD, et al. Enfermedad renal diabética: puesta al día. An Fac Cienc Méd. 2022;55(3):86-98. https://doi.org/10.18004/anales/2022.055.03.86
Marso SP, Daniels GH, Frandsen KB, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. https://doi.org/10.1056/NEJMoa1603827
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. https://doi.org/10.1016/S0140-6736(19)31149-3
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-44. https://doi.org/10.1056/NEJMoa1607141
Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diabetes Rep. 2019;19. https://doi.org/10.1007/s11892-019-1123-8
Ruilope LM, Tamargo J. Renin-angiotensin system blockade: Finerenone. Nephrol Ther. 2017;13(supl. 1):S47-53. https://doi.org/10.1016/j.nephro.2017.02.003
Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Curr Cardiol Rep. 2020;22. https://doi.org/10.1007/s11886-020-01399-7
Vodošek-Hojs N, Bevc S, Ekart R, Piko N, Petreski T, Hojs R. Mineralocorticoid receptor antagonists in diabetic kidney disease. Pharmaceuticals. 2021;14(6):561. https://doi.org/10.3390/ph14060561
Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol. 2003;284(1). https://doi.org/10.1152/ajpheart.00421.2002
Erraez S, López-Mesa M, Gómez-Fernández P. Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica. Nefrología. 2021;41(3):258-75. https://doi.org/10.1016/j.nefro.2020.10.001
Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013;34(31). https://doi.org/10.1093/eurheartj/eht187
Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-32. https://doi.org/10.1002/ejhf.218
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50:333-44. https://doi.org/10.1159/000503713
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-29. https://doi.org/10.1056/NEJMoa2025845
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385:2252-63. https://doi.org/10.1056/NEJMoa2110956
American Diabetes Association. Introduction: Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(supl. 1):S1-2. https://doi.org/10.2337/dc22-Sint
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the Fidelity pooled analysis. Eur Heart J. 2022;43(6):474-84. https://doi.org/10.1093/eurheartj/ehab777
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and kidney disease: Improving Global Outcomes (Kdigo). Diabetes Care. 2022. https://doi.org/10.2337/dci22-0027
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.